Physician profile
Sonya Bellamy
NPI 1780638627
$7,994.25
in general payments reported to CMS, 2019-2025
35 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $163 · 2021: $725 · 2022: $1,265 · 2023: $1,390 · 2024: $2,583 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,337 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,337.20 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,685.93 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $938.62 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $571.52 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $514.10 | 2019-2025 | |
| Janssen Biotech, INC. | $486.37 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $443.88 | 2022-2025 | Sotyktu |
| Pfizer INC. | $385.80 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $316.23 | 2020-2025 | Winlevi, Ilumya |
| Incyte Corporation | $313.64 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $312.83 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Dermavant Sciences, INC. | $242.39 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $217.41 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $198.16 | 2023-2024 | Zoryve |
| Amgen INC. | $196.88 | 2021-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $148.41 | 2023-2024 | Olumiant, Taltz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $127.20 | 2019-2025 | Seysara |
| Ucb, INC. | $120.70 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $116.67 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.60 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.40 | 2022-2025 | Jublia, Siliq, Targretin |
| Sanofi-Aventis U.S. LLC | $78.91 | 2021 | |
| Biofrontera INC. | $59.30 | 2021-2022 | |
| Epi Health, LLC | $55.21 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $40.22 | 2023-2024 | Ycanth |
| Journey Medical Corporation | $35.15 | 2025 | |
| Vyne Pharmaceuticals INC. | $28.28 | 2021 | |
| Dusa Pharmaceuticals, INC. | $20.72 | 2019 | |
| Botanix Sb INC | $17.71 | 2025 | Sofdra |
| Genentech USA, INC. | $16.43 | 2021 | |
| Prugen, INC. Pharmaceuticals | $15.35 | 2020 | |
| Hydrofera LLC | $14.92 | 2024 | Hydrofera Blue |
| Teva Pharmaceuticals USA, INC. | $14.41 | 2024 | |
| Organogenesis INC. | $14.31 | 2021 | |
| Stemline Therapeutics INC. | $13.58 | 2020 | |
| Strata Skin Sciences, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Bellamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.